secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001104659-23-116008
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics Q3 net loss $32.7M, appoints Brent Pfeiffenberger CEO
--------------------------------------------------------------------------

- Brent Pfeiffenberger appointed CEO effective Dec 4, 2023; Greg Russotti becomes Chief Technology and Manufacturing Officer.
- Cash and investments $284.3M as of Sep 30, 2023; cash runway into 2026.
- Q3 2023 net loss $32.7M vs $30.7M in Q3 2022; R&D expenses down to $22.8M from $25.9M.
- Expanded license with FUJIFILM Cellular Dynamics for iPSC-derived cell therapies in autoimmune/inflammatory diseases.
- Initial Phase 1 ELiPSE-1 data for CNTY-101 in B-cell lymphomas to be presented at ASH Dec 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465923116008/0001104659-23-116008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465923116008/tm2330170d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-116008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer